Biocon
Sustainability Report and Carbon Intensity Rankings
Is Biocon doing their part?
Their DitchCarbon score is 61
Biocon has a DitchCarbon Score of 61, indicating a moderate level of sustainability in their operations. This score reflects the company’s efforts to manage and reduce its carbon intensity. A higher score would suggest even greater success in minimizing their environmental impact through lower carbon emissions.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Biocon operates in the services industry, which has a very low carbon intensity ranking. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Biocon, located in India, operates in a region with a very high carbon intensity rating. This suggests that the company’s sustainability efforts may be significantly challenged by the high carbon emissions associated with the local energy grid and industrial practices.
Unlock 30+ emissions data points on Biocon
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Biocon
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
17.15%
...this company is doing 17.15% better in emissions than the industry average.
Founded in 1978 and headquartered in Bengaluru, India, Biocon Ltd. is a leading biopharmaceutical company that specializes in developing innovative and affordable healthcare solutions. The company has made significant strides in the biopharma industry by introducing products such as recombinant human Insulin and novel biologics for chronic diseases like diabetes, cancer, and autoimmune disorders. With a growing global presence, Biocon is expanding its operations with a state-of-the-art facility in Malaysia, aiming to meet the increasing demand for affordable insulin and insulin analogs worldwide.
emission intelligence's platform recommendations for Biocon
Biocon should enhance its energy efficiency by adopting measures across all forms of purchased energy, potentially reducing its emissions by 30%.
Good news, Biocon has embraced SBTi climate commitments
Biocon has pledged to align its operations and strategies with the Science Based Targets initiative to significantly reduce greenhouse gas emissions. This commitment involves setting science-based environmental targets to limit global warming and transition to a low-carbon economy.
Participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.